Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzymegene

BMC Medical Genetics

Table 4 Interaction analysis of insulin degrading enzyme 2 (SNP rs4646953) genotype

parameter (baseline/risk)	examination	slope (95% CI)	p-value
IDE2 (T/C)	baseline	20.72 (6.23 - 35.21)	0.005
AD (no/yes)		-7.45 (-50.34 - 35.45)	0.73
IDE2 × AD		-	-
IDE2 (T/C)	1^st follow-up	13.60 (-6.92 - 34.11)	0.19
AD (no/yes)		7.36 (-23.75 - 38.48)	0.64
IDE2 × AD		33.91 (-22.02 - 89.84)	0.24
IDE2 (T/C)	2^nd follow-up	21.41 (-3.43 - 46.25)	0.09
AD (no/yes)		36.27 (3.72 - 68.82)	0.03
IDE2 × AD		76.89 (24.01 - 129.77)	0.005

Analysis of interaction of insulin degrading enzyme SNP rs4646953 (IDE2) genotype and Alzheimer's disease (AD) status on amyloid β₄₂ (Aβ₄₂) plasma level is shown. Effect sizes and nominal p-values were derived from multivariate regression analysis with sex and presence of apolipoprotein E (APOE ε4) alleles as covariates. Nominally significant p-values (p < 0.05) are shown in bold.

ISSN: 1471-2350